Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;12(1):6-15.
doi: 10.1007/s11904-014-0254-4.

Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era

Affiliations
Review

Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era

Cristina Brickman et al. Curr HIV/AIDS Rep. 2015 Mar.

Abstract

Human papillomavirus (HPV) infection is associated with essentially all cervical cancers, 80-90 % of anal cancers, and a high proportion of oropharyngeal, vaginal, penile, and vulvar cancers. Malignancy is preceded by the development of precancerous lesions termed high-grade squamous intraepithelial lesions (HSIL). Men and women with human immunodeficiency virus (HIV) infection are at high risk of HPV-related malignancies. The incidence of anal cancer in particular has markedly risen during the antiretroviral era due to the increased longevity of patients with HIV and the absence of anal malignancy screening programs. HIV infection may facilitate initial HPV infection by disrupting epithelial cell tight junctions. Once infection is established, HIV may promote HSIL development via the up-regulation of HPV oncogene expression and impairment of the immune response needed to clear the lesion. HIV-infected women should be screened for cervical HSIL and cancer, and HIV-infected men and women should be considered for anal screening programs.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Am Osteopath Assoc. 2006 Mar;106(3 Suppl 1):S2-8 - PubMed
    1. Mucosal Immunol. 2008 Jan;1(1):23-30 - PubMed
    1. J Clin Oncol. 2012 Dec 10;30(35):4360-6 - PubMed
    1. J Natl Cancer Inst. 2008 Apr 2;100(7):513-7 - PubMed
    1. J Infect Dis. 2010 Nov 15;202(10):1567-76 - PubMed

MeSH terms

Substances